The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?

Sep 3, 2020

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Sarita Rani Jaiswal, Dharamshila Narayana Superspeciality Hospital, New Delhi, IN. We asked, Why can CTLA4Ig-primed sequential donor lymphocyte infusion (DLI) improve chronic GvHD and relapse-free survival (RFS) after allogeneic hematopoietic stem cell transplant (allo-HSCT)?

Why can CTLA4Ig-primed sequential DLI improve chronic GvHD and RFS after allo-HSCT?

CTLA4Ig can block costimulation, and therefore activation, of T cells by binding to CD80 and CD86 on antigen-presenting cells. This effect is selective for T cells, as natural killer cells are resistant to CTLA4Ig-mediated anergy and in fact show an increased antitumor action. Sarita Rani Jaiswal's group has used this unique property of CTLA4Ig in the clinic to improve chronic GvHD.